76 related articles for article (PubMed ID: 7680311)
1. The metal-dependent conformational changes in factor IX associated with phospholipid binding. Studies using antibodies against a synthetic peptide and chemical modification of factor IX.
Liebman HA
Eur J Biochem; 1993 Mar; 212(2):339-45. PubMed ID: 7680311
[TBL] [Abstract][Full Text] [Related]
2. The factor IX phospholipid-binding site is required for calcium-dependent activation of factor IX by factor XIa.
Liebman HA; Furie BC; Furie B
J Biol Chem; 1987 Jun; 262(16):7605-12. PubMed ID: 3108254
[TBL] [Abstract][Full Text] [Related]
3. Factor IX Zutphen: a Cys18-->Arg mutation results in formation of a heterodimer with alpha 1-microglobulin and the inability to form a calcium-induced conformation.
Wojcik EG; van den Berg M; van der Linden IK; Poort SR; Cupers R; Bertina RM
Biochem J; 1995 Nov; 311 ( Pt 3)(Pt 3):753-9. PubMed ID: 7487929
[TBL] [Abstract][Full Text] [Related]
4. Membrane binding properties of the factor IX gamma-carboxyglutamic acid-rich domain prepared by chemical synthesis.
Jacobs M; Freedman SJ; Furie BC; Furie B
J Biol Chem; 1994 Oct; 269(41):25494-501. PubMed ID: 7929250
[TBL] [Abstract][Full Text] [Related]
5. Identification of residues in the Gla-domain of human factor IX involved in the binding to conformation specific antibodies.
Wojcik EG; Cheung WF; van den Berg M; van der Linden IK; Stafford DW; Bertina RM
Biochim Biophys Acta; 1998 Jan; 1382(1):91-101. PubMed ID: 9507074
[TBL] [Abstract][Full Text] [Related]
6. Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX.
Freedman SJ; Blostein MD; Baleja JD; Jacobs M; Furie BC; Furie B
J Biol Chem; 1996 Jul; 271(27):16227-36. PubMed ID: 8663165
[TBL] [Abstract][Full Text] [Related]
7. Structure of the calcium ion-bound gamma-carboxyglutamic acid-rich domain of factor IX.
Freedman SJ; Furie BC; Furie B; Baleja JD
Biochemistry; 1995 Sep; 34(38):12126-37. PubMed ID: 7547952
[TBL] [Abstract][Full Text] [Related]
8. Localization of a calcium-dependent epitope to the amino terminal region of the Gla domain of human factor IX.
Cheung WF; Stafford DW; Sugo T
Thromb Res; 1996 Jan; 81(1):65-73. PubMed ID: 8747521
[TBL] [Abstract][Full Text] [Related]
9. Modification of the N-terminus of human factor IX by defective propeptide cleavage or acetylation results in a destabilized calcium-induced conformation: effects on phospholipid binding and activation by factor XIa.
Wojcik EG; Van Den Berg M; Poort SR; Bertina RM
Biochem J; 1997 May; 323 ( Pt 3)(Pt 3):629-36. PubMed ID: 9169594
[TBL] [Abstract][Full Text] [Related]
10. Localization of the specific binding site for magnesium(II) ions in factor IX.
Sekiya F; Yoshida M; Yamashita T; Morita T
FEBS Lett; 1996 Sep; 392(3):205-8. PubMed ID: 8774845
[TBL] [Abstract][Full Text] [Related]
11. Prothrombin requires two sequential metal-dependent conformational transitions to bind phospholipid. Conformation-specific antibodies directed against the phospholipid-binding site on prothrombin.
Borowski M; Furie BC; Bauminger S; Furie B
J Biol Chem; 1986 Nov; 261(32):14969-75. PubMed ID: 2429962
[TBL] [Abstract][Full Text] [Related]
12. gamma-Carboxyglutamic acids 36 and 40 do not contribute to human factor IX function.
Gillis S; Furie BC; Furie B; Patel H; Huberty MC; Switzer M; Foster WB; Scoble HA; Bond MD
Protein Sci; 1997 Jan; 6(1):185-96. PubMed ID: 9007991
[TBL] [Abstract][Full Text] [Related]
13. Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody.
Huang M; Furie BC; Furie B
J Biol Chem; 2004 Apr; 279(14):14338-46. PubMed ID: 14722079
[TBL] [Abstract][Full Text] [Related]
14. Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding properties.
Ware J; Diuguid DL; Liebman HA; Rabiet MJ; Kasper CK; Furie BC; Furie B; Stafford DW
J Biol Chem; 1989 Jul; 264(19):11401-6. PubMed ID: 2738071
[TBL] [Abstract][Full Text] [Related]
15. Structural determinants of the factor IX molecule mediating interaction with the endothelial cell binding site are distinct from those involved in phospholipid binding.
Ryan J; Wolitzky B; Heimer E; Lambrose T; Felix A; Tam JP; Huang LH; Nawroth P; Wilner G; Kisiel W
J Biol Chem; 1989 Dec; 264(34):20283-7. PubMed ID: 2555350
[TBL] [Abstract][Full Text] [Related]
16. Antibody-probed conformational transitions in the protease domain of human factor IX upon calcium binding and zymogen activation: putative high-affinity Ca(2+)-binding site in the protease domain.
Bajaj SP; Sabharwal AK; Gorka J; Birktoft JJ
Proc Natl Acad Sci U S A; 1992 Jan; 89(1):152-6. PubMed ID: 1729682
[TBL] [Abstract][Full Text] [Related]
17. Sequence-specific 1H NMR assignments, secondary structure, and location of the calcium binding site in the first epidermal growth factor like domain of blood coagulation factor IX.
Huang LH; Cheng H; Pardi A; Tam JP; Sweeney WV
Biochemistry; 1991 Jul; 30(30):7402-9. PubMed ID: 1854745
[TBL] [Abstract][Full Text] [Related]
18. Characterization of gamma-carboxyglutamic acid residue 21 of human factor IX.
Wolberg AS; Li L; Cheung WF; Hamaguchi N; Pedersen LG; Stafford DW
Biochemistry; 1996 Aug; 35(32):10321-7. PubMed ID: 8756687
[TBL] [Abstract][Full Text] [Related]
19. Localization of a metal-dependent epitope to the amino terminal residues 33-40 of human factor IX.
Cheung WF; Wolberg AS; Stafford DW; Smith KJ
Thromb Res; 1995 Dec; 80(5):419-27. PubMed ID: 8588203
[TBL] [Abstract][Full Text] [Related]
20. Profactor IX: the propeptide inhibits binding to membrane surfaces and activation by factor XIa.
Bristol JA; Freedman SJ; Furie BC; Furie B
Biochemistry; 1994 Nov; 33(47):14136-43. PubMed ID: 7947825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
